USD

View All

the business cocktail
AgomAb Therapeutics raises $23.5M; Allergan’s eye drug; Good news for the patients; Dyne Therapeutics comes to life

AgomAb Therapeutics raises USD 23.5 million for its agomAbs A Belgian biotherapeutics company AgomAb Therapeutics which has been in a long run of making agonistic antibodies has secured USD 23.5 million in a Series A financing round from international investor syndicate co-led by V-Bio Ventures (Belgium) and Adv...

Find More

merck
The Business Cocktail

Biohaven buys PRV from GW Pharmaceuticals for USD 105 million GW Pharmaceuticals has announced its decision to sell its rare pediatric disease priority review voucher (PRV) to Biohaven Pharmaceuticals. The voucher was issued under U.S. Food and Drug Administration programme to accelerate speedy recovery of rare ...

Find More

Women Healthcare
Where Women Healthcare Stands

Technology has made an impact on every field. And Healthcare is no exception. Advances in medical technology have proven to be a game-changer in the health sector. But is the case same when Women healthcare comes to mind? It will not be less than a shock to learn that Women were not included in medical research and...

Find More

wearable
Wearing Technology to stay fit

Did you know that wearable technology, which consists of sports and activity trackers, accounts for nearly USD 700 Million of the healthcare industry? Moreover, analysts have assessed that the share of Wearable Devices Market is going to hit more than USD 50 Billion, by 2022. A lot of us assume that to track our st...

Find More

mRNA
Biogen buys Nightstar; Pacira acquires Myoscience; Horizon Pharma announces pricing; STAT with Slingshot Insights; Epizyme announces Equity Offering

Biogen to buy Nightstar for USD 800 Million Biogen known for its efforts in treatments of multiple sclerosis and spinal muscular atrophy wound up the deal to buy Nightstar. The deal will let Biogen have access to two experimental gene therapies for blindness-causing diseases helping Biogen’s pipeline. Pacira...

Find More

Cost ineffective Orphan Drugs limit the access

Rare diseases are mostly serious, chronic and life-threatening, associated with both psychological as well as financial burdens. In addition, only a few of them have effective drug treatment available. The European Union (EU) definition of a rare disease is one that affects fewer than 5 in 10,000 people. These affe...

Find More